Jump to main content
Jump to site search

Issue 11, 2010
Previous Article Next Article

Bioprospecting for antituberculosis leads from microbial metabolites

Author affiliations

Abstract

Covering: 2005 to 2010

Microbial metabolites have been an important source of tuberculosis (TB) therapeutics, but the last truly novel drug that was approved for the treatment of TB was discovered 40 years ago. In light of the growing threat of multi-drug resistance, recent advances have been made to accelerate the discovery rate of novel TB drugs including diversifying strategies for environmental strains, and high-throughput screening assays. This review will discuss the approaches used in biodiversity- and taxonomy-guided microbial natural product library construction, specific cell-based and target-based high-throughput screening assays and early-stage dereplication processes by liquid chromatographymass spectrometry (LCMS). New antituberculosis natural products that have been recently discovered are highlighted.

Graphical abstract: Bioprospecting for antituberculosis leads from microbial metabolites

Back to tab navigation

Article information


Submitted
24 Jun 2010
First published
04 Oct 2010

Nat. Prod. Rep., 2010,27, 1709-1719
Article type
Review Article

Bioprospecting for antituberculosis leads from microbial metabolites

E. J. Ashforth, C. Fu, X. Liu, H. Dai, F. Song, H. Guo and L. Zhang, Nat. Prod. Rep., 2010, 27, 1709
DOI: 10.1039/C0NP00008F

Social activity

Search articles by author

Spotlight

Advertisements